Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Ontunisertib · AGMB-129, ORG-129

Small molecule · developed by Agomab Spain S.L.U.

Phase 2 Most advanced trial
AGMB Developer
2 Registered trials

What is Ontunisertib?

Ontunisertib is an investigational small-molecule drug studied in Fibrostenotic Crohn's Disease.

At a glance

Also known as
AGMB-129, ORG-129
Drug type
Small molecule
Therapy area
Gastroenterology
Developer
Agomab Spain S.L.U. (AGMB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
SF6HGC94LK

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07683325 Phase 2 Fibrostenotic Crohn's Disease Recruiting AGMB
NCT07672574 Phase 1 Fibrostenotic Crohn's Disease Recruiting AGMB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fibrostenotic Crohn's Disease

More from Agomab Spain S.L.U.

AGMB-447 Phase 2

Follow AGMB, the company behind Ontunisertib

See AGMB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AGMB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.